113 related articles for article (PubMed ID: 2137903)
1. Making chemotherapy easier.
Grunberg SM
N Engl J Med; 1990 Mar; 322(12):846-8. PubMed ID: 2137903
[No Abstract] [Full Text] [Related]
2. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
[TBL] [Abstract][Full Text] [Related]
3. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
Marty M
Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S41-5. PubMed ID: 2533898
[TBL] [Abstract][Full Text] [Related]
4. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Kris MG; Tyson LB; Clark RA; Gralla RJ
Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
[TBL] [Abstract][Full Text] [Related]
5. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
6. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community.
Hickok JT; Roscoe JA; Morrow GR; King DK; Atkins JN; Fitch TR
Cancer; 2003 Jun; 97(11):2880-6. PubMed ID: 12767103
[TBL] [Abstract][Full Text] [Related]
7. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
Mitchell PL; Evans BD; Allan SG; Forgeson GV; Mak D; Neave L; Humm G; Langley G; Dickson D; Harvey VJ
N Z Med J; 1992 Mar; 105(929):73-5. PubMed ID: 1532054
[TBL] [Abstract][Full Text] [Related]
8. Ondansetron to prevent vomiting after cancer chemotherapy.
Med Lett Drugs Ther; 1991 Jun; 33(847):63-4. PubMed ID: 1828531
[No Abstract] [Full Text] [Related]
9. Ondansetron; further progress in the prevention of nausea and vomiting induced by anti-cancer chemotherapy.
Sagar SM; Bayliss MA; Chong SL; Retsas S
Clin Oncol (R Coll Radiol); 1991 May; 3(3):183. PubMed ID: 1829958
[No Abstract] [Full Text] [Related]
10. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J
N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902
[TBL] [Abstract][Full Text] [Related]
11. The role of ondansetron in paediatric patients: a review of three studies.
Stevens RF
Eur J Cancer; 1991; 27 Suppl 1():S20-2. PubMed ID: 1831631
[TBL] [Abstract][Full Text] [Related]
12. [Serotonin as mediator in vomiting reflex: effect of a serotonin3 receptor antagonist in chemotherapy-induced vomiting].
Layer P
Z Gastroenterol; 1991 May; 29(5):265-6. PubMed ID: 1835227
[No Abstract] [Full Text] [Related]
13. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
Egan AP; Taggart JR; Bender CM
Oncol Nurs Forum; 1992 Jun; 19(5):791-5. PubMed ID: 1535124
[TBL] [Abstract][Full Text] [Related]
14. Are granisetron and ondansetron equivalent in the clinic?
Dilly S
Eur J Cancer; 1992; 28A Suppl 1():S32-5. PubMed ID: 1320918
[TBL] [Abstract][Full Text] [Related]
15. [A randomized trial of Zudan in the prophylaxis of nausea and vomiting induced by cisplatin].
Huang J; Wang Z; Zhou L
Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):153-4. PubMed ID: 10920971
[TBL] [Abstract][Full Text] [Related]
16. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
Hamadani M; Awab A; Chaudhary L; Tfayli A
J Oncol Pharm Pract; 2006 Jun; 12(2):67-8. PubMed ID: 16984743
[No Abstract] [Full Text] [Related]
17. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
Gandara DR; Harvey WH; Monaghan GG; Perez EA; Stokes C; Bryson JC; Finn AL; Hesketh PJ
Semin Oncol; 1992 Aug; 19(4 Suppl 10):67-71. PubMed ID: 1387253
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study].
Ikeda M; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Akasaka Y; Ohta J; Suminaga M
Gan To Kagaku Ryoho; 1992 Sep; 19(11):1905-14. PubMed ID: 1387776
[TBL] [Abstract][Full Text] [Related]
19. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
20. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
